Results for tag: "Imbruvica"

Imbruvica is a drug used to treat certain types of leukemia, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is a kinase inhibitor, meaning it works by blocking certain proteins that help cancer cells grow and divide. It is taken orally, usually once a day. Imbruvica is approved by the US Food and Drug Administration (FDA) for the treatment of CLL and MCL, and is also being studied for other types of cancer. The Imbruvica market is highly competitive, with several companies offering similar drugs. These include AbbVie, Johnson & Johnson, and Pharmacyclics. AbbVie markets Imbruvica in the US, while Johnson & Johnson markets it in Europe. Pharmacyclics is the developer of Imbruvica and holds the rights to the drug in the US and Europe. Other companies in the market include Gilead Sciences, Celgene, and Novartis. Show Less Read more